Business Monitor International


Netherlands Pharmaceuticals & Healthcare Report

Published 25 November 2014

  • 120 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Netherlands Pharmaceuticals & Healthcare Report

BMI View: Despite the Dutch economy expanding during the second quarter of 2014 at a time were the broader Eurozone have slowed, we believe the Netherlands ' patented and generic drugmakers face difficult challenges over the coming years. The government will likely remain committed to reduce drug prices as it tries to cope with the healthcare demands of a growing aging population. This coupled with a patent cliff along with health insurers looking to include cheaper generic medicines into their policies, keeps our outlook for the market subdued.

  Headline Expenditure Projections

  • Pharmaceuticals: EUR6.09bn (USD8.04bn) in 2013 to EUR5.92bn (USD7.93bn) in 2014; -2.8% in local currency terms and -1.3% in US dollar terms.

  • Healthcare: EUR70.37bn (USD92.89bn) in 2013 to EUR71.34bn (USD95.59bn) in 2014; 1.4% in local currency terms and 2.9% in US dollar terms.

Risk/Reward Index

The Netherlands continues to rank in the lower half of BMI's Pharmaceutical Risk/Reward Indices (RRIs) for the 15 key Western European markets, remaining 12th for Q115. The country fell from eighth in Q413. At 65.1, its overall RRI score remains slightly below the regional average of 68. This was the result of the rise of Finland and the incorporation of Denmark in our ratings system, both of which overtook the Netherlands. While the country offers drugmakers a relatively low-risk operating environment, poor market prospects - due to pressures on pricing and reimbursement and the market's maturity - will continue to weigh down its overall standing.

Key Trends And Developments

October

  • to-BBB has reported significant additions to complete its new management team in addition to changing its name from to-BBB technologies to BBB Therapeutics. Dr Ferdinand Massari and Dr Pericles Calias have joined BBB as Chief Medical Officer and Chief Scientific Officer. Completing the management team are recently appointed CEO Dr Anders Harfstrand, CFO Leon Kruimer and Chief Business Officer Dr Carlos de...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Netherlands 2010-2018)
16
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2010-2018)
19
Prescription Drug Market Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)
22
Patented Drug Market Forecast
23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)
24
Netherlands
24
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)
26
OTC Medicine Market Forecast
26
Table: OTC Medicine Sales Indicators By Category, 2008-2010
28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Netherlands 2010-2018)
29
Pharmaceutical Trade Forecast
30
Table: Pharmaceutical Trade Data And Forecast (Netherlands 2012-2018)
31
Table: Pharmaceutical Trade Data And Forecasts local currency (Netherlands 2012-2018)
31
Other Healthcare Data
32
Table: Number Of Physicians By Type, 2007-2010
33
Key Risks To BMI's Forecast Scenario
33
Macroeconomic Forecasts
35
Economic Analysis
35
Table: Netherlands - Economic Activity
38
Industry Risk Reward Ratings
39
Western Europe Risk/Reward Ratings
39
Netherlands Risk/Reward Ratings
44
Rewards
44
Risks
44
Market Overview
46
Industry Trends And Developments
47
Epidemiology
47
Healthcare Sector
48
Healthcare Funding
50
Health Insurance
51
Table: Key Points Of The Dutch Health Insurance Act, January 1 2006
52
Healthcare Insurance Developments
56
Table: Biosimilars Approved In The EU
57
Research And Development
57
Clinical Trials
60
Biotechnology
63
Regulatory Development
64
Regulatory Developments
65
Intellectual Property Regime
67
Pricing Regime
68
Reimbursement Regime
70
Competitive Landscape
73
Pharmaceutical Industry
73
Table: Pharmaceutical Production, 1995-2010 (EUR '000s)
73
Recent Company Activity
75
Pharmaceutical Wholesale Sector
77
Pharmaceutical Retail Sector
78
Company Profile
81
DSM
81
Qiagen
85
Pharming Group
88
Merck & Co
92
Pfizer
95
GlaxoSmithKline
98
Sanofi
100
Novartis
102
Demographic Forecast
105
Demographic Outlook
105
Table: The Netherlands' Population By Age Group, 1990-2020 ('000)
106
Table: The Netherlands' Population By Age Group, 1990-2020 (% of total)
107
Table: The Netherlands' Key Population Ratios, 1990-2020
108
Table: The Netherlands' Rural And Urban Population, 1990-2020
108
Glossary
109
Methodology
111
Pharmaceutical Expenditure Forecast Model
111
Healthcare Expenditure Forecast Model
111
Notes On Methodology
112
Risk/Reward Ratings Methodology
113
Ratings Overview
114
Table: Pharmaceutical Risk/Reward Ratings Indicators
114
Indicator Weightings
115

The Netherlands Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Netherlands Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Dutch pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Netherlands to test other views - a key input for successful budgeting and strategic business planning in the Dutch pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Dutch pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Netherlands.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc